Zacks Small Cap Research – MGRM: Monogram’s Potential for Profitable Long-Term Growth Supports Price Target of $6.00. – Go Health Pro
By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Monogram (NASDAQ:MGRM) reported 3rd quarter 2024 financial results on November 14th which were largely in line with expectations. Research and development expenses for the quarter ending September 30, 2024 were $2.2 million compared to $2.7 million in the prior year period. The R&D decrease … Read more
